we are developing car t therapies for hematologic malignancies in partnership with coh targeting cd123 ( mb-102 ) and cs1 ( mb-104 ) and with fred hutch targeting cd20 ( mb-106 ) . phase 1 clinical trials sponsored by coh for mb-102 and mb-104 and by fred hutch for mb-106 are underway . in the third quarter of 2019 the fda approved our ind application to initiate a multicenter phase 1/2 clinical trial of mb-102 , and our clinical trial is expected to begin enrollment in the first half of 2020 for the treatment of patients with acute myeloid leukemia , blastic plasmacytoid dendritic cell neoplasm , and high-risk myelodysplastic syndrome . we expect to file an ind for mb-104 in the second half of 2020 and to initiate our own phase 1 clinical trial shortly thereafter for the treatment of patients with multiple myeloma . we also plan to file an ind and initiate our own clinical trial for mb-106 for the treatment of patients with non-hodgkin lymphoma and chronic lymphocytic leukemia . we are also developing car t therapies for solid tumors in partnership with coh targeting il13r a 2 ( mb-101 ) , her2 ( mb-103 ) and psca ( mb-105 ) . in addition , we have partnered with nationwide for the c134 oncolytic virus ( mb-108 ) in order to enhance the activity of mb-101 for the treatment of patients with gbm . phase 1 clinical trials sponsored by coh for mb-101 , mb-103 and mb-105 are underway . a phase 1 clinical trial sponsored by uab for mb-108 began during the third quarter of 2019 and , in the second half of 2020 , we plan to file an ind for the combination of mb-101 and mb-108 for the treatment of patients with gbm . we also plan to file inds and initiate our own clinical trials for mb-103 for the treatment of patients with metastatic breast cancer to brain and for mb-105 for the treatment of patients with prostate and pancreatic cancer . recent events mb-101 ( il13rα2 car t for glioblastoma ) in october 2019 , mustang announced that coh received $ 4.1 million in grant awards for a clinical trial of mb-101 ( il13rα2-targeted car t ) in combination with nivolumab ( commercial name : opdivo® ) and ipilimumab ( commercial name : yervoy® ) in patients with recurrent malignant glioma . the trial , which is now enrolling patients , is the first human study to combine il13rα2-targeted car t cell therapy with checkpoint inhibitors , as well as the first to locally deliver car t cells with systemic nivolumab combination treatment . additional information on the trial can be found on www.cinicaltrials.gov using identifier nct04003649 . mb-105 ( psca car t for prostate & pancreatic cancers ) in september 2019 , we announced that coh had opened and initiated patient treatments in a phase 1 clinical trial of mb-105 , a psca car t technology for the treatment of prostate cancer . additional information on the phase 1 trial can be found on www.cinicaltrials.gov using identifier nct03873805 . 50 mb-102 ( cd123 car t for aml ) on august 5 , 2019 , we announced that the fda had approved our ind application to initiate a multi-center phase 1/2 clinical trial of mb-102 ( cd123 car t ) in acute myeloid leukemia ( “ aml ” ) , blastic plasmacytoid dendritic cell neoplasm ( “ bpdcn ” ) and high-risk myelodysplastic syndrome ( “ hrmds ” ) . we will begin enrollment on our mb-102 clinical trial in the first half of 2020 and process patient cells in our manufacturing facility , which opened in june 2018. additional information on the trial can be found on www.cinicaltrials.gov using identifier nct04109482 . in july 2019 , we announced that the fda had granted orphan drug designation to mb-102 ( cd123 car t ) for the treatment of aml . the fda also previously granted orphan drug designation to mb-102 for the treatment of bpdcn . the fda grants orphan drug designation to drugs and biologics that are intended for the safe and effective treatment , diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the u.s. orphan drug designation provides certain incentives , such as tax credits toward the cost of clinical trials and prescription drug user fee waivers . if a product holding orphan drug designation receives the first fda approval for the disease in which it has such designation , the product is entitled to seven years of market exclusivity , which is independent from intellectual property protection . mb-103 ( her2 car t for gbm & metastatic breast cancer to brain ) in august 2019 , we announced that the california institute for regenerative medicine had awarded a $ 9.3 million grant to dr. saul priceman at coh to conduct a phase 1 clinical trial evaluating the safety and effectiveness of intraventricular delivery of her2-directed car t cells to the brains of patients with her2-positive breast cancer with brain metastases . city of hope exclusively licensed mb-103 to us in 2017. additional information on the phase 1 trial can be found on www.cinicaltrials.gov using identifier nct03696030 . mb-106 ( cd20-targeted car t cell therapy ) in february 2020 , we announced that the first subject treated with the optimized mb-106 ( cd20-targeted , autologous car t cell therapy ) manufacturing process , developed in collaboration between mustang and fred hutch , has achieved a complete response ( cr ) at the lowest starting dose in an ongoing phase 1/2 clinical trial . the phase 1/2 , open-label , dose-escalation trial is evaluating the maximum tolerated dose of mb-106 . secondary endpoints include safety and toxicity , preliminary antitumor activity as measured by overall response rate and complete remission rate , progression-free survival , and overall survival . story_separator_special_tag no sales were made under the 2018 mustang atm in 2018. public offering of common stock on april 30 , 2019 , we announced the pricing of an underwritten public offering , whereby we sold 6,875,000 shares of common stock , ( plus a 30-day option to purchase up to an additional 1,031,250 shares of common stock , which was fully exercised ) at a price of $ 4.00 per share for gross proceeds of approximately $ 31.6 million , before deducting underwriting discounts and commissions and offering expenses . in connection with the public offering , the company paid aggregate fees of approximately $ 2.1 million for net proceeds of approximately $ 29.5 million . the shares were sold under the 2018 mustang s-3 , filed with the securities and exchange commission . the offering closed on may 2 , 2019 , and the over-allotment closing was on may 8 , 2019. authorized stock on august 16 , 2019 , the company 's board adopted resolutions of the board to ratify , approve and recommend stockholder approval of an amendment to the company 's amended and restated certificate of incorporation , as amended , to revise article iv , authorized stock thereof in order to effect an increase in the authorized number of shares of the company 's common stock , par value $ 0.0001 , from 50.0 million to 85.0 million ( the “ amendment ” ) . on august 16 , 2019 , the company received approval of the amendment by written consent in lieu of a meeting from the holders of a majority of issued and outstanding shares of the company 's common and preferred stock . the increase in authorized shares to 85.0 million became effective on september 30 , 2019. to date , we have not received approval for the sale of our product candidates in any market and , therefore , have not generated any product sales from our product candidates . in addition , we have incurred substantial operating losses since our inception , and expect to continue to incur significant operating losses for the foreseeable future and may never become profitable . as of december 31 , 2019 , we have an accumulated deficit of $ 125.5 million . 52 we are a majority-controlled subsidiary of fortress biotech , inc. ( “ fortress ” ) . as a “ controlled company ” we rely on the exemption provided by nasdaq listing rule 5615 ( c ) ( 2 ) , which permits us to maintain less than a majority of independent directors on our board . critical accounting policies and use of estimates see note 2 to our financial statements . results of operations comparison of the years ended december 31 , 2019 and 2018 replace_table_token_1_th research and development expenses research and development expenses primarily consist of personnel related expenses , including salaries , benefits , travel , and other related expenses , stock-based compensation , payments made to third parties for license , sponsored research and milestone costs related to in-licensed products and technology , payments made to third party contract research organizations for preclinical and clinical studies , investigative sites for clinical trials , consultants , the cost of acquiring and manufacturing clinical trial materials , costs associated with regulatory filings , laboratory costs and other supplies . for the year ended december 31 , 2019 , research and development expenses were approximately $ 30.0 million , compared to approximately $ 21.1 million , an increase of $ 8.9 million . for the year ended december 31 , 2019 , research and development expenses primarily consisted of $ 6.1 million for sponsored research and clinical trial agreements with our academic partners , $ 7.8 million for personnel compensation and benefits , $ 0.9 million for stock compensation expense , $ 4.4 million for laboratory supplies , $ 3.2 million related to consulting and outside services , $ 3.6 million for clinical trial costs , $ 0.9 million related to facility costs , and $ 1.3 million depreciation expense . for the year ended december 31 , 2018 , research and development expenses primarily consisted of $ 5.7 million for sponsored research and clinical trial agreements with our academic partners , $ 4.3 million for personnel compensation and benefits , $ 3.4 million for stock compensation expense , $ 2.3 million for laboratory supplies , $ 1.1 million related to consulting and outside services , $ 0.5 million related to facility costs , and $ 0.6 million depreciation expense . for the year ended december 31 , 2019 , research and development expenses - licenses acquired were approximately $ 6.3 million , compared to approximately $ 3.4 million , an increase of $ 2.9 million . for the year ended december 31 , 2019 , research and development expenses - licenses acquired consisted of $ 4.9 million for the annual stock dividend to fortress , $ 0.2 million for an upfront fee for our license with nationwide children 's hospital , $ 0.2 million for our license with csl behring ( calimmune ) , $ 0.3 million for a development milestone paid to ucla in connection with mb-105 and $ 0.7 million in connection with our licenses with coh . for the year ended december 31 , 2018 , research and development expenses - licenses acquired consisted of $ 2.1 million for the annual stock dividend to fortress , $ 1.0 million for an upfront fee for our license with st. jude for the treatment of xscid and $ 0.3 million in connection with our licenses with coh . we expect our research and development activities to increase as we develop our existing product candidates and potentially acquire new product candidates , reflecting increasing costs associated with the following : · employee-related expenses , which include salaries and benefits ; · license fees and milestone payments related to in-licensed products and technology ; · expenses incurred under agreements with contract

liquidity and capital resources the company has incurred substantial operating losses and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable . as of december 31 , 2019 , the company had an accumulated deficit of $ 125.5 million . the company has funded its operations to date primarily through the sale of equity . the company expects to continue to use the proceeds from previous financing transactions primarily for general corporate purposes , including financing the company 's growth , developing new or existing product candidates , and funding capital expenditures , acquisitions and investments . the company currently anticipates that its cash and cash equivalents balances as of december 31 , 2019 , are sufficient to fund its anticipated operating cash requirements for at least one year from the date of this form 10-k. the company will be required to expend significant funds in order to advance the development of its product candidates . the company 's estimates as to how long it expects its existing cash to be able to continue to fund its operations is based on assumptions that may prove to be inaccurate , and it could use its available capital resources sooner than it currently expects , as a result of unforeseen events . such changes in circumstances may require that the company alter development plans of certain of its product candidates .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources the company has incurred substantial operating losses and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable . as of december 31 , 2019 , the company had an accumulated deficit of $ 125.5 million . the company has funded its operations to date primarily through the sale of equity . the company expects to continue to use the proceeds from previous financing transactions primarily for general corporate purposes , including financing the company 's growth , developing new or existing product candidates , and funding capital expenditures , acquisitions and investments . the company currently anticipates that its cash and cash equivalents balances as of december 31 , 2019 , are sufficient to fund its anticipated operating cash requirements for at least one year from the date of this form 10-k. the company will be required to expend significant funds in order to advance the development of its product candidates . the company 's estimates as to how long it expects its existing cash to be able to continue to fund its operations is based on assumptions that may prove to be inaccurate , and it could use its available capital resources sooner than it currently expects , as a result of unforeseen events . such changes in circumstances may require that the company alter development plans of certain of its product candidates .
```    
 Suspicious Activity Report : we are developing car t therapies for hematologic malignancies in partnership with coh targeting cd123 ( mb-102 ) and cs1 ( mb-104 ) and with fred hutch targeting cd20 ( mb-106 ) . phase 1 clinical trials sponsored by coh for mb-102 and mb-104 and by fred hutch for mb-106 are underway . in the third quarter of 2019 the fda approved our ind application to initiate a multicenter phase 1/2 clinical trial of mb-102 , and our clinical trial is expected to begin enrollment in the first half of 2020 for the treatment of patients with acute myeloid leukemia , blastic plasmacytoid dendritic cell neoplasm , and high-risk myelodysplastic syndrome . we expect to file an ind for mb-104 in the second half of 2020 and to initiate our own phase 1 clinical trial shortly thereafter for the treatment of patients with multiple myeloma . we also plan to file an ind and initiate our own clinical trial for mb-106 for the treatment of patients with non-hodgkin lymphoma and chronic lymphocytic leukemia . we are also developing car t therapies for solid tumors in partnership with coh targeting il13r a 2 ( mb-101 ) , her2 ( mb-103 ) and psca ( mb-105 ) . in addition , we have partnered with nationwide for the c134 oncolytic virus ( mb-108 ) in order to enhance the activity of mb-101 for the treatment of patients with gbm . phase 1 clinical trials sponsored by coh for mb-101 , mb-103 and mb-105 are underway . a phase 1 clinical trial sponsored by uab for mb-108 began during the third quarter of 2019 and , in the second half of 2020 , we plan to file an ind for the combination of mb-101 and mb-108 for the treatment of patients with gbm . we also plan to file inds and initiate our own clinical trials for mb-103 for the treatment of patients with metastatic breast cancer to brain and for mb-105 for the treatment of patients with prostate and pancreatic cancer . recent events mb-101 ( il13rα2 car t for glioblastoma ) in october 2019 , mustang announced that coh received $ 4.1 million in grant awards for a clinical trial of mb-101 ( il13rα2-targeted car t ) in combination with nivolumab ( commercial name : opdivo® ) and ipilimumab ( commercial name : yervoy® ) in patients with recurrent malignant glioma . the trial , which is now enrolling patients , is the first human study to combine il13rα2-targeted car t cell therapy with checkpoint inhibitors , as well as the first to locally deliver car t cells with systemic nivolumab combination treatment . additional information on the trial can be found on www.cinicaltrials.gov using identifier nct04003649 . mb-105 ( psca car t for prostate & pancreatic cancers ) in september 2019 , we announced that coh had opened and initiated patient treatments in a phase 1 clinical trial of mb-105 , a psca car t technology for the treatment of prostate cancer . additional information on the phase 1 trial can be found on www.cinicaltrials.gov using identifier nct03873805 . 50 mb-102 ( cd123 car t for aml ) on august 5 , 2019 , we announced that the fda had approved our ind application to initiate a multi-center phase 1/2 clinical trial of mb-102 ( cd123 car t ) in acute myeloid leukemia ( “ aml ” ) , blastic plasmacytoid dendritic cell neoplasm ( “ bpdcn ” ) and high-risk myelodysplastic syndrome ( “ hrmds ” ) . we will begin enrollment on our mb-102 clinical trial in the first half of 2020 and process patient cells in our manufacturing facility , which opened in june 2018. additional information on the trial can be found on www.cinicaltrials.gov using identifier nct04109482 . in july 2019 , we announced that the fda had granted orphan drug designation to mb-102 ( cd123 car t ) for the treatment of aml . the fda also previously granted orphan drug designation to mb-102 for the treatment of bpdcn . the fda grants orphan drug designation to drugs and biologics that are intended for the safe and effective treatment , diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the u.s. orphan drug designation provides certain incentives , such as tax credits toward the cost of clinical trials and prescription drug user fee waivers . if a product holding orphan drug designation receives the first fda approval for the disease in which it has such designation , the product is entitled to seven years of market exclusivity , which is independent from intellectual property protection . mb-103 ( her2 car t for gbm & metastatic breast cancer to brain ) in august 2019 , we announced that the california institute for regenerative medicine had awarded a $ 9.3 million grant to dr. saul priceman at coh to conduct a phase 1 clinical trial evaluating the safety and effectiveness of intraventricular delivery of her2-directed car t cells to the brains of patients with her2-positive breast cancer with brain metastases . city of hope exclusively licensed mb-103 to us in 2017. additional information on the phase 1 trial can be found on www.cinicaltrials.gov using identifier nct03696030 . mb-106 ( cd20-targeted car t cell therapy ) in february 2020 , we announced that the first subject treated with the optimized mb-106 ( cd20-targeted , autologous car t cell therapy ) manufacturing process , developed in collaboration between mustang and fred hutch , has achieved a complete response ( cr ) at the lowest starting dose in an ongoing phase 1/2 clinical trial . the phase 1/2 , open-label , dose-escalation trial is evaluating the maximum tolerated dose of mb-106 . secondary endpoints include safety and toxicity , preliminary antitumor activity as measured by overall response rate and complete remission rate , progression-free survival , and overall survival . story_separator_special_tag no sales were made under the 2018 mustang atm in 2018. public offering of common stock on april 30 , 2019 , we announced the pricing of an underwritten public offering , whereby we sold 6,875,000 shares of common stock , ( plus a 30-day option to purchase up to an additional 1,031,250 shares of common stock , which was fully exercised ) at a price of $ 4.00 per share for gross proceeds of approximately $ 31.6 million , before deducting underwriting discounts and commissions and offering expenses . in connection with the public offering , the company paid aggregate fees of approximately $ 2.1 million for net proceeds of approximately $ 29.5 million . the shares were sold under the 2018 mustang s-3 , filed with the securities and exchange commission . the offering closed on may 2 , 2019 , and the over-allotment closing was on may 8 , 2019. authorized stock on august 16 , 2019 , the company 's board adopted resolutions of the board to ratify , approve and recommend stockholder approval of an amendment to the company 's amended and restated certificate of incorporation , as amended , to revise article iv , authorized stock thereof in order to effect an increase in the authorized number of shares of the company 's common stock , par value $ 0.0001 , from 50.0 million to 85.0 million ( the “ amendment ” ) . on august 16 , 2019 , the company received approval of the amendment by written consent in lieu of a meeting from the holders of a majority of issued and outstanding shares of the company 's common and preferred stock . the increase in authorized shares to 85.0 million became effective on september 30 , 2019. to date , we have not received approval for the sale of our product candidates in any market and , therefore , have not generated any product sales from our product candidates . in addition , we have incurred substantial operating losses since our inception , and expect to continue to incur significant operating losses for the foreseeable future and may never become profitable . as of december 31 , 2019 , we have an accumulated deficit of $ 125.5 million . 52 we are a majority-controlled subsidiary of fortress biotech , inc. ( “ fortress ” ) . as a “ controlled company ” we rely on the exemption provided by nasdaq listing rule 5615 ( c ) ( 2 ) , which permits us to maintain less than a majority of independent directors on our board . critical accounting policies and use of estimates see note 2 to our financial statements . results of operations comparison of the years ended december 31 , 2019 and 2018 replace_table_token_1_th research and development expenses research and development expenses primarily consist of personnel related expenses , including salaries , benefits , travel , and other related expenses , stock-based compensation , payments made to third parties for license , sponsored research and milestone costs related to in-licensed products and technology , payments made to third party contract research organizations for preclinical and clinical studies , investigative sites for clinical trials , consultants , the cost of acquiring and manufacturing clinical trial materials , costs associated with regulatory filings , laboratory costs and other supplies . for the year ended december 31 , 2019 , research and development expenses were approximately $ 30.0 million , compared to approximately $ 21.1 million , an increase of $ 8.9 million . for the year ended december 31 , 2019 , research and development expenses primarily consisted of $ 6.1 million for sponsored research and clinical trial agreements with our academic partners , $ 7.8 million for personnel compensation and benefits , $ 0.9 million for stock compensation expense , $ 4.4 million for laboratory supplies , $ 3.2 million related to consulting and outside services , $ 3.6 million for clinical trial costs , $ 0.9 million related to facility costs , and $ 1.3 million depreciation expense . for the year ended december 31 , 2018 , research and development expenses primarily consisted of $ 5.7 million for sponsored research and clinical trial agreements with our academic partners , $ 4.3 million for personnel compensation and benefits , $ 3.4 million for stock compensation expense , $ 2.3 million for laboratory supplies , $ 1.1 million related to consulting and outside services , $ 0.5 million related to facility costs , and $ 0.6 million depreciation expense . for the year ended december 31 , 2019 , research and development expenses - licenses acquired were approximately $ 6.3 million , compared to approximately $ 3.4 million , an increase of $ 2.9 million . for the year ended december 31 , 2019 , research and development expenses - licenses acquired consisted of $ 4.9 million for the annual stock dividend to fortress , $ 0.2 million for an upfront fee for our license with nationwide children 's hospital , $ 0.2 million for our license with csl behring ( calimmune ) , $ 0.3 million for a development milestone paid to ucla in connection with mb-105 and $ 0.7 million in connection with our licenses with coh . for the year ended december 31 , 2018 , research and development expenses - licenses acquired consisted of $ 2.1 million for the annual stock dividend to fortress , $ 1.0 million for an upfront fee for our license with st. jude for the treatment of xscid and $ 0.3 million in connection with our licenses with coh . we expect our research and development activities to increase as we develop our existing product candidates and potentially acquire new product candidates , reflecting increasing costs associated with the following : · employee-related expenses , which include salaries and benefits ; · license fees and milestone payments related to in-licensed products and technology ; · expenses incurred under agreements with contract

